Edition:
India

Prevail Therapeutics Inc (PRVL.OQ)

PRVL.OQ on NASDAQ Stock Exchange Global Market

15.54USD
6 Dec 2019
Change (% chg)

-- (--)
Prev Close
$15.54
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,621
52-wk High
$16.90
52-wk Low
$7.66

Latest Key Developments (Source: Significant Developments)

Prevail To Begin Enrollment For Phase 1/2 Trial For Pr001 In First Half Of 2020
Wednesday, 11 Sep 2019 

Sept 10 (Reuters) - Prevail Therapeutics Inc ::PREVAIL THERAPEUTICS PROVIDES PROGRAM UPDATE ON PR001 IN PARKINSON’S DISEASE WITH GBA1 MUTATIONS AND NEURONOPATHIC GAUCHER DISEASE.PREVAIL - START OF PHASE 1/2 TRIAL FOR PR001 IN NGD IS ANTICIPATED TO BE DELAYED ABOUT 1 QUARTER, TO BEGIN ENROLLMENT IN FIRST HALF OF 2020.PREVAIL THERAPEUTICS INC - MODIFICATION TO NGD PHASE 1/2 TRIAL DESIGN IS NOT ANTICIPATED TO DELAY OVERALL TIMELINE TO TRIAL COMPLETION.  Full Article

Prevail Therapeutics Receives U.S. FDA Fast Track Designation For PR001 For The Treatment Of Parkinson’s Disease Patients With A GBA1 Mutation
Monday, 8 Jul 2019 

July 8 (Reuters) - Prevail Therapeutics Inc ::PREVAIL THERAPEUTICS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR PR001 FOR THE TREATMENT OF PARKINSON’S DISEASE PATIENTS WITH A GBA1 MUTATION.PREVAIL THERAPEUTICS INC - ON TRACK TO BEGIN DOSING PATIENTS IN A PHASE 1/2 CLINICAL TRIAL IN SECOND HALF OF 2019.  Full Article

Prevail Therapeutics Inc Says Anticipates Initial Public Offering Price Will Be Between $16.00 And $18.00 Per Share - SEC Filing
Monday, 10 Jun 2019 

June 10 (Reuters) - Prevail Therapeutics Inc ::PREVAIL THERAPEUTICS INC SAYS ANTICIPATES INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $16.00 AND $18.00 PER SHARE - SEC FILING.PREVAIL THERAPEUTICS INC SEES IPO OF UP TO 7.35 MILLION SHARES OF COMMON STOCK.  Full Article